These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 25349236)

  • 1. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA; Kolesar JM
    Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W; Tufman A; Huber RM
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
    Keating GM
    Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
    Bowles DW; Weickhardt A; Jimeno A
    Drugs Today (Barc); 2013 Sep; 49(9):523-35. PubMed ID: 24086949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
    Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
    J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.